Overview of Flector Patch

Quick Facts

Property	Description
Active Ingredient	Diclofenac epolamine
Form	Transdermal Patch / Topical System
Pharmacological Class	Nonsteroidal Anti-inflammatory Drug (NSAID)
Common Use	Localized relief of acute pain and swelling
Origin	Synthetic

Defining the Diclofenac Epolamine Topical System

The Diclofenac Epolamine Topical System, known commercially as Flector Patch, is a prescription-only medicine classified as a Nonsteroidal Anti-inflammatory Drug (NSAID). This product is a transdermal patch or self-adhesive medicated topical system designed for topical application.

This medication functions as an NSAID and a non-opioid analgesic, placing it within the pharmacological category used to manage pain and inflammation. The medicated patch is a distinguishing feature, allowing for steady, controlled delivery of the active agent directly to the target area.

Composition and Localized Action

The central active ingredient is Diclofenac epolamine, a synthetic salt of diclofenac, contained within a specialized hydrogel base. The patch is engineered for a gradual and consistent release of medicine.

Setting this formulation apart from many other diclofenac products is the use of the epolamine salt, which is specifically utilized because it enhances the compound's permeability, facilitating effective topical delivery across the skin barrier. This design ensures localized action and achieves minimal systemic absorption. The primary function of the diclofenac is to inhibit the production of prostaglandins, the chemicals that mediate inflammation and pain signals, thus concentrating the therapeutic effect.

General Purpose and Benefit

The general therapeutic purpose of the Diclofenac Epolamine Topical System is to provide targeted anti-inflammatory activity and pain relief. The patch is often employed in situations requiring focused support, such as addressing acute pain associated with sprains or contusions.

As a non-opioid analgesic, its primary benefit lies in offering focused relief through a controlled topical method. This provides a strategic approach for managing localized soft tissue discomfort, which is its established clinical use.

Regulatory References

What side effects are possible with Flector Patch?

Possible Side Effects and Safety Information

The safety profile of the Diclofenac Epolamine Topical System is characterized by both localized reactions and the potential for systemic adverse events associated with its pharmacological class, Nonsteroidal Anti-inflammatory Drugs (NSAIDs). All documented side effects and safety statements are based on official government regulatory documents.

Adverse Reaction Classifications

The most frequently reported adverse events are localized application site reactions, which are classified as common. These typically include pruritus (itching), dermatitis, and a burning sensation at the site of patch application, falling under the Skin and Subcutaneous Tissue Disorders system-organ class. Systemic effects, such as headache and certain gastrointestinal complaints, are also listed as common or uncommon.

Serious Systemic Risks and Safety Constraints

Due to minimal, yet present, systemic absorption, the regulatory labeling includes warnings for serious NSAID-associated risks. These include the potential for serious cardiovascular thrombotic events, such as myocardial infarction and stroke, and serious gastrointestinal adverse events, including bleeding, ulceration, and perforation. The risk of these serious events may increase with the duration of use.

Specific safety restrictions include the product being contraindicated for patients with a known hypersensitivity to diclofenac or other NSAIDs, and its prohibition for pain management in the peri-operative setting of Coronary Artery Bypass Graft (CABG) surgery. Additionally, the patch is contraindicated during the third trimester of pregnancy.

Overdose and Emergency Response

Overdose and When to Seek Help — Official Regulatory Information

The potential for overdose, which may occur from massive topical misuse or oral ingestion, is primarily assessed based on the systemic toxicity profile of the active ingredient, diclofenac, an NSAID.

Overdose manifestations described in regulatory documents primarily involve the gastrointestinal (GI), cardiovascular (CV), and central nervous systems (CNS).

System	Documented Overdose Presentations
Gastrointestinal	Nausea, vomiting (sometimes with blood), stomach pain, diarrhea, GI bleeding, and potential perforation.
Systemic/CNS	Drowsiness, dizziness, confusion, high or low blood pressure, increased heart rate, and severe CNS events like seizures or coma in cases of massive overdose.

When Immediate Medical Help is Required (Label-Derived Phrasing):

Official labeling mandates that the patient seek immediate medical attention or get emergency medical help right away if symptoms indicative of serious systemic events occur. This includes chest pain, shortness of breath, weakness on one side of the body, slurred speech, or signs of GI bleeding such as black, tarry stools, or vomiting blood.

Overdose Management and Risk Factors:

The management of systemic overdose is symptomatic and supportive, as no specific antidote is known to reverse the effects of diclofenac toxicity. Supportive measures may include monitoring vital signs, blood/urine tests, ECG, and the administration of activated charcoal for recent ingestion. Regulatory documents note that elderly patients and those with a prior history of CV disease or GI bleeding are documented as being at greater risk for serious, sometimes fatal, outcomes like myocardial infarction, stroke, or GI perforation.

Therapeutic Uses of Flector Patch

What Flector Patch Treats: Main Uses and Benefits

The Diclofenac Epolamine Topical System is commonly used for managing acute, localized symptomatic discomfort stemming from specific soft tissue injuries. The topical system is commonly used for the localized relief of acute pain symptoms associated with minor strains, sprains, and contusions in adults and pediatric patients 6 years and older.

Relief from Acute Soft Tissue Injuries

This therapeutic domain is commonly used across conditions presenting with acute episodes of localized trauma. It is applied across domains where additional symptomatic support is needed to address the initial phases following an injury, focusing on the acute pain and related inflammation. This application is often relevant in scenarios such as sports-related trauma or other post-traumatic events where minor soft tissue injury occurs.

Management of Localized Inflammatory Symptoms

The medication is relevant for easing symptoms related to inflammatory or irritative states, specifically the pain and swelling that cluster together at the injury site. This supportive relief contributes to improved day-to-day comfort during periods of heightened symptoms by assisting with the overall symptom load localized to the affected area. A key benefit is providing focused relief to help manage acute symptoms.

“The topical system helps address symptom clusters that may become intense or disruptive in an acute setting.”

Quick Fact: Relief for Acute Pain
The product is used to help address localized pain and swelling related to minor strains, sprains, and contusions.

Regulatory References

NIH DailyMed drug information

Eligibility and Restrictions for Use

Eligibility and Contraindications

The eligibility for the Diclofenac Epolamine Topical System (Flector Patch) is strictly defined by regulatory agencies based on age, specific medical history, and clinical status.

Category	Regulatory Status	Population
Allowed Age	Use Established	Adults and pediatric patients 6 years of age and older.
Not Established	Safety/Efficacy Unproven	Pediatric patients under 6 years of age.

Absolute Contraindications (Prohibited Use)

The patch must not be used by specific patient populations due to the risk of serious adverse events:

Patients with a known hypersensitivity to diclofenac or a history of asthma, urticaria, or other allergic-type reactions after taking aspirin or any other NSAID.
Patients in the peri-operative period of Coronary Artery Bypass Graft (CABG) surgery.
Pregnant women at or beyond 30 weeks of gestation (the third trimester).
The patch must not be applied to non-intact or damaged skin, such as open wounds, infections, or eczema.

Restricted Use Populations

Use is strongly discouraged or requires special consideration in certain populations:

Advanced renal disease or severe heart failure patients: Use should be avoided unless the benefits outweigh the risk of worsening organ function.
Breastfeeding/Lactating mothers: Use is generally not recommended as diclofenac can pass into breast milk.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory documents define the Diclofenac Epolamine Topical System's interaction profile based on the systemic effects of the Nonsteroidal Anti-inflammatory Drug (NSAID) class. The primary risks involve pharmacodynamic reinforcement leading to increased toxicity and interference with renal function affecting drug clearance.

Classification	Official Regulatory Statement
Contraindicated Combinations	Use is prohibited for the treatment of peri-operative pain in the setting of Coronary Artery Bypass Graft (CABG) surgery. It is also contraindicated in patients with a history of allergic-type reactions after taking aspirin or any other NSAID.
Pharmacodynamic Interactions	Co-administration with Anticoagulants (e.g., Warfarin) and SSRIs/SNRIs significantly increases the risk of bleeding. Concomitant use with oral NSAIDs and salicylates is officially documented to increase the risk of serious GI adverse events.
Exposure Modification	The topical system may diminish the antihypertensive effect of ACE Inhibitors/ARBs and reduce the diuretic effect of diuretics. It also produces an elevation of plasma lithium levels and increases the risk for toxicity from Methotrexate and Cyclosporine due to reduced renal clearance.
Restrictions	Alcohol consumption is cited as a risk factor that increases the risk for GI bleeding.
Population Notes	In the elderly, volume depleted, or renally impaired patients, co-administration with ACE Inhibitors/ARBs may lead to deterioration of renal function.

These official interaction statements establish clear regulatory constraints on co-administration, grounded in the NSAID's systemic effects.

Mechanism of Action

The mechanism of action for the Diclofenac Epolamine system is defined by its highly targeted influence on the body's local chemical signaling, resulting in a physiological response characterized by decreased local inflammatory markers and reduced nociceptor sensitization.

Enzymatic Inhibition of Prostaglandin Synthesis

The active ingredient engages enzyme-mediated signaling by reversibly blocking the Cyclooxygenase-1 (COX-1) and Cyclooxygenase-2 (COX-2) enzymes. This action modifies early molecular steps that influence the downstream physiological response by suppressing the conversion of arachidonic acid into prostanoids like prostaglandin E2 ( PGE2).

Modulation of Local Inflammatory and Pain Pathways

This blockade creates a localized effect on the arachidonic acid cascade. The resulting lower concentration of PGE2 contributes to the modulation of mediator activity, which in turn reduces capillary vasodilation and vascular permeability. This physiological adjustment reduces fluid extravasation (edema) and decreases the excitability of peripheral nociceptors.

Peripheral Mechanism Specificity

The formulation is engineered to engage mechanisms that regulate dysregulated processes predominantly in the peripheral tissues, applied to influence the signaling state within targeted pathways. This localized focus means the mechanism's activity is concentrated on peripheral pathways rather than on central nervous system (CNS) targets.

Dosage and Administration Information

How to Use Flector Patch

The Diclofenac Epolamine Topical System (Flector Patch) is a prescription-only medication that is administered exclusively via the topical route. The standard approach to use is guided by the principle of applying the lowest effective dose for the shortest duration necessary to meet treatment objectives.

Administration and Dosing Schedule

Parameter	Official Instruction
Route of Administration	Topical (applied directly to the skin).
Standard Dose	One (1) topical system per application.
Frequency	Applied twice daily (approximately every 12 hours).
Maximum Dose	The frequency allows for a maximum of two patches per day.

Application and Procedural Guidelines

The topical system is applied directly to the most painful area of the body. The skin at the application site must be intact, clean, and dry; the patch must not be placed over non-intact skin, wounds, or open lesions. The standard regimen for use applies to both adults and pediatric patients 6 years of age and older, with the same dose of one patch twice daily.

To maintain effective use, the patch must not be covered by an occlusive (airtight) bandage or dressing. If necessary, non-occlusive supports, such as mesh netting, may be used. Furthermore, the patch must not be worn while showering or bathing. If a dose is missed, the patient should skip the missed application if it is nearly time for the next scheduled dose; otherwise, they should apply a new patch as soon as it is remembered. Hands must be washed immediately after handling, applying, or removing the topical system.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Flector Patch

Evidence for Use in Acute Pain from Minor Strains and Sprains

The primary research for the diclofenac epolamine patch centered on conditions associated with acute, localized discomfort, such as minor strains, sprains, and contusions. The research examined the medicine's properties in these contexts. The evidence base includes short-term, double-blind Randomized Controlled Trials (RCTs). These studies were used in research exploring how symptoms change over time, comparing the medicated patch to a non-medicated, inactive patch (placebo). Outcomes related to physical discomfort and patient-reported outcomes describing perceived discomfort were measured to assess patterns that were observed in the study populations. Findings described patterns observed in the studies related to how patients reported their experience over a follow-up duration that was limited to about one to two weeks.

Studies on Localized Drug Delivery and Systemic Exposure

Research also examined the fundamental properties of the patch as a topical system through Pharmacokinetic (PK) studies. These studies were applied in research contexts involving how the medicine is delivered and absorbed. Studies measured diclofenac plasma concentrations, which are outcomes related to systemic imbalance, in both healthy adult volunteers and patient populations to assess how much of the medicine entered the bloodstream.

PK studies reported measurements of minimal systemic absorption when compared to the absorption patterns of oral diclofenac formulations. Data described patterns related to a slow and continuous delivery of the ingredient, which is consistent with the localized delivery profile examined in the studies. Comparative evidence with other topical diclofenac products remains lacking in the core regulatory documentation.

Long-Term Research and Evidence Gaps

The majority of pivotal studies exploring changes in symptoms during acute conditions were designed for short-term follow-up, specifically lasting between 7 and 14 days. These durations reflect the typical acute phase of the conditions for which the product was studied for. Therefore, the evidence base is concentrated on outcomes describing episodic or acute changes in symptoms.

Key research limitations include the short duration of follow-up, meaning that the long-term outcomes were not measured. Furthermore, some early trial findings were mixed, and data for certain groups, such as those with chronic conditions or those over 65, remain limited. The clinical studies provide context but not individual predictions for how an individual may respond, and study results reflect the specific conditions under which they were conducted.

Key Studies & References Flector (diclofenac epolamine) topical system Labeling (Current Prescribing Information, DailyMed)

Frequently Asked Questions (FAQ)

Common questions about Flector Patch (FAQ)

Q: Is Flector Patch the same as diclofenac pills or gel?

Flector Patch is described in official documents as a topical system that delivers diclofenac to the site of pain. Studies indicate that the medicine has minimal systemic absorption (entering the bloodstream), in contrast to formulations designed for systemic delivery.

Q: Why do doctors prescribe the Flector Patch instead of oral pain relievers?

Regulatory information indicates that the patch is designed to achieve a localized action where it is applied. This method of delivery is associated with lower systemic absorption of the drug compared to taking a medicine by mouth.

Q: Can the Flector Patch be used for knee pain or only ankle/foot injuries?

The patch is indicated for the treatment of acute pain associated with minor soft-tissue injuries such as strains and sprains. Official instructions guide applying the patch to the most painful area of the body, provided the skin at that site is clean and intact.

Q: Is the patch meant for chronic pain or only acute injuries?

According to the official product indication, the patch is for the treatment of acute pain (short-term, sudden pain) due to minor injuries. The research evidence supporting the patch's use is concentrated on studies with a short-term follow-up, typically lasting 7 to 14 days.

Q: What happens if the Flector Patch falls off before the full time is up?

Official instructions for a missed application (or a patch falling off) state that if it is nearly time for the next scheduled dose (approximately 12 hours), the application should be skipped. Otherwise, regulatory guidance suggests applying a new patch as soon as possible.

Q: Is it normal to feel a warming or cooling sensation where the patch is applied?

Common reactions at the application site listed in regulatory documents include pruritus (itching), dermatitis, and a burning sensation. Warming or cooling sensations are not cited as a typical or common reported adverse event in official product information.

Q: Does the Flector Patch affect my stomach lining the same way oral NSAIDs do?

The patch is associated with minimal systemic absorption. The risk of serious gastrointestinal adverse events (like bleeding or ulcers) is described as reduced compared to oral NSAIDs due to minimal systemic exposure. However, because it is an NSAID, the potential for these systemic events remains listed as a safety warning.

Q: How long can a person typically use the Flector Patch treatment?

The official indication for the patch is for the short-term treatment of acute pain associated with minor injuries. The duration of the clinical studies used for regulatory review was limited, typically lasting no more than 14 days.

Q: Can I apply sunscreen or lotion on the skin before applying the patch?

Official application instructions state that the patch must be applied to intact, clean, and dry skin only. The presence of other topical products, such as sunscreens or lotions, at the application site may affect how the drug is absorbed or adheres.

Q: Does sun exposure or tanning beds pose a risk while using the patch?

Regulatory documents indicate the potential for photosensitivity reactions (increased sensitivity to light). The official product information advises protecting the application site from natural and artificial sunlight (such as tanning beds) during treatment and for a period following use.

Q: Is the amount of medication absorbed from the patch different for everyone?

Pharmacokinetic studies have examined the pattern of systemic exposure (how much medicine enters the bloodstream) in patient populations. While the overall systemic exposure is described as minimal, individual patient factors may influence the specific amount of medicine absorbed.

Q: What should I do if the area where I applied the patch develops a rash?

Application site reactions, including dermatitis (rash) and pruritus (itching), are commonly reported adverse events. Regulatory patient information provides guidance on when to discontinue use and consult a healthcare professional if persistent skin irritation occurs.

Q: Are there any special considerations for older adults using this patch?

Official labeling includes warnings regarding the use of NSAIDs in older adults, especially concerning potential effects on renal function when combined with specific medications. Research evidence for the product in patients over 65 years of age is described as limited.

Q: Do other medications I take affect how much of the drug gets absorbed?

Regulatory documents cite several known drug interactions. These interactions modify the body's overall exposure or the pharmacodynamic effects (how the drug acts in the body) by affecting drug clearance or increasing risks like bleeding.

Q: Can I use the patch if I have high blood pressure?

Official regulatory documents warn that NSAIDs can potentially lead to the new onset or worsening of pre-existing hypertension (high blood pressure). Official documents suggest that blood pressure monitoring may be necessary during treatment with NSAIDs in this patient group.

Q: Why does the label warn about using other topical products in the same area?

Application instructions specify that the patch must be applied only to intact, clean, and dry skin. The label warns against applying the patch over damaged or non-intact skin, such as open wounds or skin affected by conditions like eczema or exudative dermatitis.

Q: How is the Flector Patch different from a regular heat patch?

Flector Patch is a prescription-only transdermal system that delivers a specific medicine, the NSAID diclofenac epolamine, to address pain and inflammation. A regular heat patch provides thermal relief only and does not contain any medication.

Q: Are there known cases of dependence or addiction related to this patch?

According to official classification, the Diclofenac Epolamine Topical System is not listed as a controlled substance. The medicine in the patch is a non-opioid NSAID and is not associated with dependence or addiction.

Q: Is it okay to sleep with the Flector Patch on?

The patch is applied twice daily, approximately every 12 hours. This duration of application means the patch is designed to be worn continuously for the full 12-hour dosing period, which includes periods of rest and sleep.

How should Flector Patch be stored and disposed of?

How to Store and Dispose of Flector Patch?

This information is based strictly on regulatory guidance for storage and disposal.

Flector Patch must be stored at Controlled Room Temperature, specifically between 20 C and 25 C (68 F and 77 F), with permitted temperature excursions up to 30 C (86 F). The patch must be protected from moisture and kept in the original sealed pouch until use. Once the pouch is opened, the patch must be applied immediately.

Storage Requirement	Condition
Temperature	20 C to 25 C (68 F to 77 F)
Protection	Keep in original sealed pouch; Protect from moisture
In-Use Stability	Apply immediately upon opening pouch

For disposal, the used Flector Patch should be folded so that the adhesive side sticks to itself. The folded patch must then be discarded immediately and kept out of the reach of children and pets. Do not flush the patch down the toilet.

Flector Patch